{"id":81062,"date":"2026-06-10T22:01:35","date_gmt":"2026-06-10T22:01:35","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/81062\/"},"modified":"2026-06-10T22:01:35","modified_gmt":"2026-06-10T22:01:35","slug":"roche-pumps-480-million-into-south-korea-biopharma-industry","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/81062\/","title":{"rendered":"Roche pumps $480 million into South Korea biopharma industry"},"content":{"rendered":"<p>Roche is plugging 710 billion won (about $484 million) into South Korea\u2019s biopharma industry, with the goal of attracting global clinical trials and cultivating talent in the East Asian nation.<\/p>\n<p>Roche signed a memorandum of understanding (MOU) with the Ministry of Health and Welfare solidifying the pledge, a Roche spokesperson confirmed to Fierce Biotech.<\/p>\n<p>\u201cThis partnership is expected to strengthen the core competitiveness of Korea\u2019s bio-healthcare industry by establishing an ecosystem for global clinical trials and enhancing R&amp;D capabilities for innovative medicines,\u201d the spokesperson said.<\/p>\n<p>\u201cWe expect that signing this MOU will not only take Korea&#8217;s clinical trial competitiveness to the next level but also serve as a catalyst for the rapid growth and global expansion of promising domestic biohealth companies,\u201d Jeong Eun-kyeong, M.D., Ph.D., South Korea\u2019s minister of health and welfare, reportedly told the <a href=\"https:\/\/www.asiae.co.kr\/en\/article\/bio-health\/2026030316135092594\" rel=\"nofollow noopener\" target=\"_blank\">Asia Business Daily<\/a>.<\/p>\n<p>The Roche partnership comes as South Korea makes a concerted effort to juice up its biopharma sector. Jeong\u2019s office <a href=\"https:\/\/www.korea.net\/Government\/Briefing-Room\/Press-Releases\/view?articleId=1489132&amp;insttCode=A260111&amp;type=N\" rel=\"nofollow noopener\" target=\"_blank\">announced a program<\/a> to help Korean biotechs secure partnerships with Big Pharmas like Roche, AbbVie and Novo Nordisk on Feb. 13.\u00a0<\/p>\n<p>The country\u2019s pharma industry was <a href=\"https:\/\/www.fortunebusinessinsights.com\/south-korea-pharmaceuticals-market-114024\" rel=\"nofollow noopener\" target=\"_blank\">estimated<\/a> to be worth $27 billion in 2024, with projections of hitting $53.97 billion in 2032, according to Fortune Business Insights.<\/p>\n<p>&#8220;Roche has long recognized Korea\u2019s distinct strengths, including the Korean government\u2019s strong commitment to fostering the biopharmaceutical industry, its highly skilled research talent, world-class clinical trial capabilities and exceptional openness to innovative technologies,&#8221; the Swiss pharma&#8217;s spokesperson added.<\/p>\n<p>Global pharma outfits strengthened their investment in South Korea by 74% between 2020 to 2024, boosting their cash infusions from 596.2 billion won ($410 million) to 1.04 trillion ($712 million), according to a report from the Korea Research-based Pharmaceutical Industry Association cited by multiple Korean outlets.<\/p>\n<p>South Korea is already known for its manufacturing industry, which includes giants like Samsung Biologics and Celltrion.<\/p>\n<p>Roche\u2019s global strategy was also on display last October, when the company&#8217;s Saudi Arabia unit signed an agreement to enhance the kingdom\u2019s clinical research capabilities\/ Saudi Arabia has expressed a vision of becoming a <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/saudi-arabia-launches-plan-become-biotech-hub-2040\" rel=\"nofollow noopener\" target=\"_blank\">global biotech hub<\/a> by 2040.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Roche is plugging 710 billion won (about $484 million) into South Korea\u2019s biopharma industry, with the goal of&hellip;\n","protected":false},"author":2,"featured_media":81063,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[1115,1288,41952,9275,41963,134,1220],"class_list":["post-81062","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-biotech","tag-clinical-trials","tag-cro","tag-fierce-biotech-homepage","tag-overseas-clinical-trials","tag-roche","tag-south-korea"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116728069006282599","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=81062"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81062\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/81063"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=81062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=81062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=81062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}